Clinical Trial Update: A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study evaluating olutasidenib in combination with hypomethylating agents for IDH1-mutated higher-risk myelodysplast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasms

Drugs mentioned

• Olutasidenib (olutasidenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms | Phase 2 | Status: RECRUITING